Atopic dermatitis imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …

This systematic review evaluates the efficacy, safety and economic impact of dupilumab
compared to standard of care for uncontrolled moderate‐to‐severe atopic dermatitis (AD) …

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense
pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a …

Background Dupilumab has proven to be an effective and safe treatment for atopic
dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are …

Purpose: This is a review of emerging targeted, systemic therapies for atopic dermatitis (AD).
The information presented aims to provide dermatologists with updated therapeutic options …

Atopic dermatitis (AD) is the most common inflammatory skin disease in children. Children
with severe AD have a multidimensional disease burden characterized by skin lesions …

Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

Introduction Dupilumab is a treatment option newly licensed for adolescents with moderate
to severe atopic dermatitis (AD). It reduces type 2 inflammation by blocking the shared …

Background Dupilumab has proven safe and effective in children and adolescents with
atopic dermatitis (AD) in clinical trials. However, comprehensive real-world studies in the …

Abstract Background and Objective Previous studies of dupilumab for the treatment of
moderate-to-severe atopic dermatitis in adults and adolescents, and severe atopic dermatitis …